Welcome to MyStrategist, the digital home for MedTech Strategist.

MedTech Strategist, the global medical device industry's most trusted resource, will help you stay ahead of the opportunities and obstacles that are impacting your corporate strategy. We invite you to explore our coverage. Think Strategically. Subscribe Today

Browse   Latest Issue
Latest from MedTech Strategist

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.


Start-Ups

Genascence: Pioneering Gene Therapy for Joint Diseases

Pioneers working on gene therapies for osteoarthritis and other chronic joint conditions won the prestigious OREF Award for 2024 at this year’s AAOS. One of the winners, Christopher Evans, PhD, discusses 30 years of research leading up to the founding of Genascence, which is now in clinical trials for a gene therapy for OA.

Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways

Start Trial
Latest from MedTech Strategist

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.


Start-Ups

Standout Strategies for Next-Gen Venous Devices

Devices for deep venous disease are having their day; the markets are becoming crowded. Second-generation movers must now find meaningful ways to differentiate themselves. MedTech Strategist interviews two companies with outside-the-box solutions: SonoVascular, in venous thrombectomy, and Auxetics, the developer of a novel venous stent. Part 2 of a 2-part review of the deep venous device market.

Don't Just Advertise... Strategize!

Advertise with MedTech Strategist and be seen by medtech's most influential executives.

Learn More
Latest from MedTech Strategist

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.


Investors & Dealmaking

Digital Health Funding: Experts Foresee Challenges Ahead

Digital health funding soared in 2021, at the height of the pandemic, but a year later began a precipitous decline. Now, with valuations way down and investors harder to come by some digital health start-ups are struggling. We take a deep dive into the current funding environment, and what is on the radar for 2024 and beyond, with the help of Janke Dittmer of Gilde Healthcare, Karl Hess of Outcome Capital, Paul Grand of MedTech Innovator, and Jonathan Norris of HSBC Innovation Banking.

Discover the opportunities and challenges that impact the global medtech regulatory and reimbursement community with Market Pathways.

Subscribe   Free Premier Issue   Learn More